Cargando…

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Bernice Ling Zhi, Tan, Nicole, de Alwis, Ruklanthi, Kunasegaran, Kamini, Chen, Zhiwei, Poon, Michelle, Chan, Esther, Low, Jenny G. H., Yeoh, Allen Eng Juh, Bertoletti, Antonio, Le Bert, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/
https://www.ncbi.nlm.nih.gov/pubmed/35472242
http://dx.doi.org/10.1182/blood.2022016166
_version_ 1784746896630218752
author Oh, Bernice Ling Zhi
Tan, Nicole
de Alwis, Ruklanthi
Kunasegaran, Kamini
Chen, Zhiwei
Poon, Michelle
Chan, Esther
Low, Jenny G. H.
Yeoh, Allen Eng Juh
Bertoletti, Antonio
Le Bert, Nina
author_facet Oh, Bernice Ling Zhi
Tan, Nicole
de Alwis, Ruklanthi
Kunasegaran, Kamini
Chen, Zhiwei
Poon, Michelle
Chan, Esther
Low, Jenny G. H.
Yeoh, Allen Eng Juh
Bertoletti, Antonio
Le Bert, Nina
author_sort Oh, Bernice Ling Zhi
collection PubMed
description Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.
format Online
Article
Text
id pubmed-9281508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-92815082022-07-15 Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients Oh, Bernice Ling Zhi Tan, Nicole de Alwis, Ruklanthi Kunasegaran, Kamini Chen, Zhiwei Poon, Michelle Chan, Esther Low, Jenny G. H. Yeoh, Allen Eng Juh Bertoletti, Antonio Le Bert, Nina Blood Letters to Blood Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia. American Society of Hematology 2022-07-14 /pmc/articles/PMC9281508/ /pubmed/35472242 http://dx.doi.org/10.1182/blood.2022016166 Text en © 2022 by The American Society of Hematology
spellingShingle Letters to Blood
Oh, Bernice Ling Zhi
Tan, Nicole
de Alwis, Ruklanthi
Kunasegaran, Kamini
Chen, Zhiwei
Poon, Michelle
Chan, Esther
Low, Jenny G. H.
Yeoh, Allen Eng Juh
Bertoletti, Antonio
Le Bert, Nina
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title_full Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title_fullStr Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title_full_unstemmed Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title_short Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
title_sort enhanced bnt162b2 vaccine-induced cellular immunity in anti-cd19 car t cell–treated patients
topic Letters to Blood
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/
https://www.ncbi.nlm.nih.gov/pubmed/35472242
http://dx.doi.org/10.1182/blood.2022016166
work_keys_str_mv AT ohbernicelingzhi enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT tannicole enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT dealwisruklanthi enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT kunasegarankamini enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT chenzhiwei enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT poonmichelle enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT chanesther enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT lowjennygh enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT yeohallenengjuh enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT bertolettiantonio enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients
AT lebertnina enhancedbnt162b2vaccineinducedcellularimmunityinanticd19cartcelltreatedpatients